Maia Biotechnology Inc. (MAIA)
AMEX AMEX Primary Summary
MAIA Biotechnology, Inc. (MAIA) Upgraded to Buy: Here's What You Should Know
MAIA Biotechnology, Inc. (MAIA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Maia Biotechnology Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| RF Rekah Franca Catalyst Funds Management Pty Ltd. | 10,800 | $15,120 | $15,606 | $486 | 3.21% |
 Lyn Dippel Curio Wealth LLC | 2,000 | $3,080 | $2,670 | -$410 | -13.31% |
 Centerpoint Advisory Group Centerpoint Advisory Group | 15,730 | $28,314 | $20,920.9 | -$7,393.1 | -26.11% |
Maia Biotechnology Inc. (MAIA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Maia Biotechnology Inc. ever had a stock split?
Maia Biotechnology Inc. Profile
| Biotechnology Industry | Healthcare Sector | Vlad Vitoc CEO | AMEX Exchange | 552641102 CUSIP |
| US Country | 13 Employees | - Last Dividend | - Last Split | 28 Jul 2022 IPO Date |
Overview
MAIA Biotechnology, Inc. is a pioneering force in the field of cancer therapy, operating at the clinical stage to bring revolutionary biotechnological solutions to the forefront of medical science. Founded in 2018 with its headquarters nestled in Chicago, Illinois, MAIA Biotechnology is committed to the identification, development, and eventual commercialization of novel treatments aimed directly at cancer. The company's spirited endeavor in targeting one of the most challenging diseases of our time underlines its foundational aim: to significantly alter the landscape of cancer treatment through innovative therapeutic approaches. With a keen focus on leveraging telomere biology to disrupt cancer cell proliferation, MAIA Biotechnology is at the cutting edge of oncological research, aspiring to offer hope to millions of patients worldwide.
Products and Services
- THIO: A Telomere-targeting Agent
At the forefront of MAIA Biotechnology's promising product pipeline stands THIO, a novel telomere-targeting agent currently undergoing rigorous scrutiny in a Phase II clinical trial. THIO embodies the company’s commitment to leveraging groundbreaking scientific advancements to combat cancer. Specifically designed to disrupt the cellular machinery responsible for the immortality of cancer cells, THIO strategically targets telomeres – the protective caps at the ends of chromosomes. By undermining the integrity of these crucial structures in cancer cells, THIO aims to induce a potent therapeutic effect against the disease. Its current evaluation in patients with non-small cell lung cancer represents a pivotal step in determining its efficacy and potential to change the trajectory of cancer treatment.
- Second Generation Telomere Targeting Agents
In its relentless pursuit of excellence in oncology, MAIA Biotechnology is also dedicating resources to the development of second generation telomere targeting agents. Building upon the foundational knowledge and promising results garnered from THIO's development, these subsequent agents are envisioned to offer enhanced precision, efficacy, and safety. By expanding its portfolio with these advanced therapeutics, MAIA Biotechnology aims not only to fortify its position within the biotechnological sphere but also to broaden the horizon of available treatments for cancer patients. This initiative underlines the company’s unwavering dedication to innovation and its enduring commitment to confronting cancer on all fronts.
